CMA alleges collusion allowed 1,800% hike in Aspen drug pricing

09-10-2019

Sarah Morgan

CMA alleges collusion allowed 1,800% hike in Aspen drug pricing

Sureeporn Teerasatean / Shutterstock.com

African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority (CMA).


CMA, competition, antitrust, NHS, Competition and Markets Authority, drug suppliers, Aspen, competition settlement, Amilco, Tiofarma

LSIPR